Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8575567 | 0.77 | CYP19A1 (0.40) | CYP3A4ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL13392640 | 0.77 | CYP19A1 (0.40) | CYP3A4ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL4185787 | 0.77 | CYP19A1 (0.40) | CYP3A4ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL7104580 | 0.77 | CYP19A1 (0.40) | CYP3A4ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL13392638 | 0.77 | CYP19A1 (0.40) | CYP3A4ALDH1A1MAPTCYP2C9CYP2C19 | |
| SCHEMBL13392645 | 0.75 | ESR1 (0.39) | ALDH1A1MAPTESR1TP53MAPK1 | |
| SCHEMBL13853950 | 0.75 | CHRM2 (0.37) | ALDH1A1MAPTTP53MAPK1CYP19A1 | |
| SCHEMBL13392653 | 0.75 | ESR1 (0.39) | ALDH1A1MAPTESR1TP53MAPK1 | |
| SCHEMBL4188211 | 0.75 | ESR1 (0.39) | ALDH1A1MAPTESR1TP53MAPK1 | |
| SCHEMBL13392644 | 0.75 | ESR1 (0.39) | ALDH1A1MAPTESR1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100009949-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20100009949-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-01-14 | — | — | US | disclosed |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007110109-A1 | NOVEL METHOD | BIOXELL SPA (IT) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007022433-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | SMN1; SMN2 4757/4885CYP3A4 1018/4885NR1I2 1015/4885 |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | CYP24A1, CYP2R1, CYP27B1 | SMN1; SMN2 4352/4885CYP3A4 172/4885NR1I2 689/4885 |
| US-20100009949-A1 | NOVEL METHOD | CYP24A1, CYP2R1, CYP27B1 | SMN1; SMN2 4848/4885CYP3A4 1785/4885NR1I2 641/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | SMN1; SMN2 4812/4885CYP3A4 4138/4885NR1I2 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.